M05.40 captures rheumatoid myopathy occurring as a systemic manifestation of rheumatoid factor-positive rheumatoid arthritis when no specific joint site is documented.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 8
- Region
- General
Documentation tips
What should appear in the chart to support M05.40.
Source · Editorial brief grounded in 5 cited references ↓
- Document RF positivity explicitly — M05 codes require seropositive RA; a lab value or prior confirmed diagnosis in the record satisfies this requirement.
- Identify the joint region primarily affected by myopathy (shoulder, knee, hand, etc.) so a site-specific M05.4x code can replace M05.40.
- Record laterality for any named joint — right, left, or bilateral — to enable the most specific 7-character code in the M05.41–M05.49 range.
- Note whether myopathy is a new manifestation or a chronic systemic finding, as this affects medical necessity language in prior-auth documentation.
- If multiple joints are involved, M05.49 (multiple sites) is more accurate than M05.40 (unspecified site) — distinguish these clearly in the A/P.
Related CPT procedures
Procedure codes commonly billed with M05.40. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M05.40 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Using M05.40 as a catch-all for complex multi-joint RA myopathy when M05.49 (multiple sites) is the correct unspecified-laterality option for documented polyarticular involvement.
- Applying M05.40 to seronegative patients — M05 requires a positive rheumatoid factor; seronegative RA myopathy belongs under M06.-.
- Submitting M05.40 on claims requiring site-specific ICD-10 codes for CMS biomarker medical necessity (LCD A56541 Group 2 lists individual joint codes, not M05.40).
- Confusing 'unspecified site' (M05.40) with 'unspecified laterality for a named joint' (e.g., M05.419 for unspecified shoulder) — these are structurally different levels of specificity.
- Coding myopathy without confirming it is documented as an RA manifestation rather than a separate primary myopathy (e.g., inflammatory myositis M60.-, polymyositis M33.2-).
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
M05.40 sits under parent category M05.4 (Rheumatoid myopathy with rheumatoid arthritis), which covers muscle weakness or atrophy arising as an extra-articular manifestation of seropositive RA. The unspecified site designation (sixth character 0) means the affected joint region has not been documented — not that myopathy is the sole finding. Because M05 requires rheumatoid factor positivity, do not use this code when RF status is negative or unknown; instead consider M06.4- (inflammatory polyarthropathy) or M06.9 (seronegative RA, unspecified).
M05.40 is the fallback within the M05.4x subcategory. Site-specific codes run from M05.41 (shoulder) through M05.49 (multiple sites), all with laterality at the seventh character (1 = right, 2 = left, 9 = unspecified for that joint). If the treating provider documents which joint is most affected — even bilaterally — a more specific code applies. Use M05.40 only when documentation genuinely lacks site information; it is not a shortcut for complex presentations.
For CMS biomarker coverage (LCD A56541), site-specific M05.4x codes are listed explicitly as supporting medical necessity for RA-related lab panels. M05.40 does not appear on that group list, so submitting it against biomarker claims may trigger a medical necessity denial. Query the provider for joint-level documentation before finalizing the code on any claim tied to RF titers, anti-CCP assays, or biologic prior-authorization requests.
Sibling codes
Other billable codes under M05.4 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01When is M05.40 appropriate instead of a site-specific M05.4x code?
02Does M05.40 require a positive rheumatoid factor?
03Can M05.40 be the principal diagnosis on a claim for a biologic injection?
04What is the difference between M05.40 and M05.49?
05Should M05.40 be used with a separate code for the RA?
06Does M05.40 apply to juvenile rheumatoid arthritis with myopathy?
07Is M05.40 valid for RA of the spine with associated myopathy?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M05-/M05.40
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M05.40
- 04cms.govhttps://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56541&ver=40&
- 05rheumatologyadvisor.comhttps://www.rheumatologyadvisor.com/diagnostic-update/rheumatology-icd-10-codes/
Mira AI Scribe
Mira's AI scribe captures RF lab status, the specific joint region exhibiting muscle weakness or atrophy, laterality, and any prior biologic or DMARD treatment history from the encounter note. That detail allows the coder to assign a site-specific M05.4x code instead of the unspecified M05.40, preventing medical necessity denials on biomarker and biologic claims.
See how Mira captures M05.40 documentation